Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

Apple’s iconic Fifth Avenue store is illuminated with iOS 18 colors as the new iPhone 16 series sale kicks off, in New York ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

Last year around this time, several leading drugmakers announced significant M&A deals to help fill their pipelines, including Bristol-Myers Squibb's ( BMY) proposed takeovers of Karuna and RayzeBio, ...

Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.